EMPOWER chart audit tool

*Note: Please complete this chart **ONLY** for patients with HR-positive HER2-negative metastatic breast cancer (mBC).*

Institution:	Patient since (month/year):

Patient demographics				
Age:	Gender (*circle*): Female Male	**Menopausal status (*circle*):** Pre/perimenopausal Postmenopausal	Ethnicity:	Body mass index:

Medical history:

Current medication list:

Stage at <u>initial</u> diagnosis:

T	M	N	Official diagnosis:
☐ 0 ☐ 1 ☐ 2 ☐ 3	☐ M0 ☐ M1	☐ 0 ☐ 1–3 ☐ 4+	

Diagnostic testing performed:

Molecular testing performed:

Initial treatment for metastatic breast cancer (mBC):

Degree of patient participation in treatment decision:
- ☐ High (ie, involved in all decisions, well informed)
- ☐ Medium (ie, understands the important aspects, though not in detail)
- ☐ Low (ie, patient depends on provider for all decisions)
- ☐ Unknown

*Please send completed chart audits to **jmcmullen**@medlearninggroup.com*

1st-line treatment included:
- ☐ Fulvestrant
- ☐ Abemaciclib + fulvestrant
- ☐ Palbociclib + fulvestrant
- ☐ Ribociclib + fulvestrant
- ☐ Tamoxifen
- ☐ Ribociclib + tamoxifen
- ☐ Exemestane + everolimus
- ☐ Fulvestrant +everolimus
- ☐ Tamoxifen + everolimus
- ☐ Capecitabine
- ☐ Intravenous (IV) chemotherapy +/– capecitabine
- ☐ Aromatase inhibitor (AI)
- ☐ Fulvestrant + AI
- ☐ Palbociclib + AI
- ☐ Ribociclib + AI
- ☐ Abemaciclib + AI
- ☐ Clinical trial: _____

Factors influencing treatment decision:
- ☐ Patient preference
- ☐ Mechanism of action of therapy
- ☐ Cost of therapy
- ☐ Clinical data
- ☐ Professional experience with therapy in practice
- ☐ Other: _____

Date of treatment initiation:	Duration of treatment:

Adverse events (AEs):

Management strategy for AE(s):

Additional members of healthcare team involved in treatment decisions for this patient (please mark all that apply):
- ☐ Oncologist
- ☐ Oncology nurse
- ☐ Nurse navigator
- ☐ Pharmacist
- ☐ Social worker
- ☐ Patient caregiver/family
- ☐ Other (please specify): _____

□ None of the above	
Progression of disease? □ Yes □ No	**Method used to detect progression:** **Please describe sites and symptoms associated with progression.**

Second-line treatment for mBC

Degree of patient participation in treatment decision:
- □ High (ie, involved in all decisions, well informed)
- □ Medium (ie, understands the important aspects, though not in detail)
- □ Low (patient depends on provider for all decisions)
- □ Unknown

Treatment (2nd line):
- □ Fulvestrant
- □ Abemaciclib + fulvestrant
- □ Palbociclib + fulvestrant
- □ Ribociclib + fulvestrant
- □ AI
- □ Palbociclib + AI
- □ Ribociclib + AI
- □ Abemaciclib + AI
- □ Tamoxifen
- □ Ribociclib + tamoxifen
- □ Exemestane + everolimus
- □ Fulvestrant +everolimus
- □ Tamoxifen + everolimus
- □ Capecitabine
- □ IV chemotherapy +/– capecitabine
- □ Abemaciclib
- □ Clinical trial_____

Factors influencing decision:
- □ Patient preference
- □ Prior therapy
- □ Mechanism of action of therapy
- □ Cost
- □ Clinical data
- □ Professional experience with therapy in practice
- □ Other: _____

Duration of treatment:	
AE(s):	
Management of AE(s):	
Additional members of healthcare team involved in decisions on patient treatment (please mark all that apply): □ Oncologist □ Oncology nurse □ Pharmacist □ Social worker □ Patient caregiver/family □ Other (please specify): _____ □ None of the above	

Progression of disease? □ Yes □ No	Date progression was detected: Method **used to** detect **progression** (diagnostic testing):
	Please describe sites and symptoms associated with progression: Therapeutic **plan:**